Deutsche Bank AG Acquires 8,134 Shares of Orchestra BioMed Holdings, Inc. $OBIO

Deutsche Bank AG grew its stake in shares of Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) by 67.3% in the first quarter, according to the company in its most recent filing with the SEC. The firm owned 20,219 shares of the company’s stock after acquiring an additional 8,134 shares during the quarter. Deutsche Bank AG owned about 0.05% of Orchestra BioMed worth $87,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. IFP Advisors Inc grew its holdings in shares of Orchestra BioMed by 106.4% during the 1st quarter. IFP Advisors Inc now owns 161,921 shares of the company’s stock valued at $693,000 after purchasing an additional 83,481 shares during the last quarter. Millennium Management LLC acquired a new stake in Orchestra BioMed in the fourth quarter valued at approximately $86,000. Bank of America Corp DE grew its stake in shares of Orchestra BioMed by 42.0% during the fourth quarter. Bank of America Corp DE now owns 23,780 shares of the company’s stock worth $95,000 after buying an additional 7,036 shares during the last quarter. Northern Trust Corp grew its stake in shares of Orchestra BioMed by 2.5% during the fourth quarter. Northern Trust Corp now owns 236,761 shares of the company’s stock worth $947,000 after buying an additional 5,725 shares during the last quarter. Finally, The Manufacturers Life Insurance Company increased its holdings in shares of Orchestra BioMed by 11.1% during the fourth quarter. The Manufacturers Life Insurance Company now owns 37,009 shares of the company’s stock worth $148,000 after buying an additional 3,704 shares in the last quarter. Institutional investors own 53.20% of the company’s stock.

Orchestra BioMed Stock Performance

Shares of OBIO stock opened at $2.73 on Tuesday. The stock has a market capitalization of $105.49 million, a PE ratio of -1.49 and a beta of 0.62. The business’s 50 day simple moving average is $2.86 and its 200 day simple moving average is $3.24. The company has a debt-to-equity ratio of 48.76, a current ratio of 2.10 and a quick ratio of 2.09. Orchestra BioMed Holdings, Inc. has a one year low of $2.37 and a one year high of $7.04.

Orchestra BioMed (NASDAQ:OBIO) last posted its quarterly earnings data on Tuesday, August 12th. The company reported ($0.50) earnings per share for the quarter, topping the consensus estimate of ($0.51) by $0.01. The firm had revenue of $0.84 million during the quarter, compared to analyst estimates of $0.78 million. Orchestra BioMed had a negative return on equity of 289.42% and a negative net margin of 2,367.49%. As a group, research analysts forecast that Orchestra BioMed Holdings, Inc. will post -1.66 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts have recently commented on OBIO shares. BTIG Research reissued a “neutral” rating on shares of Orchestra BioMed in a research note on Wednesday, August 20th. Chardan Capital reiterated a “buy” rating and set a $20.00 target price on shares of Orchestra BioMed in a research report on Wednesday, August 13th. Finally, Barclays decreased their price target on shares of Orchestra BioMed from $16.00 to $12.00 and set an “overweight” rating for the company in a research report on Monday, May 5th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $14.00.

Insider Activity at Orchestra BioMed

In other news, insider David P. Hochman acquired 20,000 shares of the business’s stock in a transaction on Monday, August 4th. The shares were purchased at an average cost of $2.75 per share, with a total value of $55,000.00. Following the acquisition, the insider directly owned 349,331 shares of the company’s stock, valued at $960,660.25. The trade was a 6.07% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders purchased 36,760 shares of company stock valued at $97,934 over the last three months. Corporate insiders own 8.10% of the company’s stock.

Orchestra BioMed Company Profile

Orchestra BioMed Holdings, Inc operates as a biomedical innovation company. The company’s flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease.